Atricure, Inc. · NASDAQ:ATRC
Atricure — Investor Presentation (November 2020)
23 slides from Atricure's investor presentation, Nov 5, 2020
Slide 1: AtriCure Investor Presentation: Creating a World Class Afib Platform
AtriCure Investor Presentation Creating a World Class Afib Platform November 2020 © 2020 AtriCure, Inc. All rights reserved. Exhibit 99.2
Slide 2: Forward-Looking Statements
This presentation contains “forward-looking statements,” which are statements related to future events that by their nature address matters that are uncertain. All forward-looking information is inherently uncertain and actual results may differ materially from assumptions, estimates or expectations
Slide 3: AtriCure Overview
AtriCure Overview © 2020 AtriCure, Inc. All rights reserved. Large Markets Addressing an underserved and growing patient population Approximately 33 million Atrial Fibrillation patients globally, with majority having advanced forms of the disease1 Multi-billion dollar annual market opportunity Curre
Slide 4: Afib: a Serious and Costly Problem
Afib: a Serious and Costly Problem Atrial Fibrillation (Afib) is an irregular heartbeat (or arrhythmia) that affects more than 33 million people worldwide.1 Approximately 1.2 million Afib diagnoses annually in the US.2 © 2020 AtriCure, Inc. All rights reserved. Afib diagnosis means: Patients with Af
Slide 5: Type of Afib matters: Concomitant and Standalone Procedures
Concomitant Open Procedures (Ablation/LAAM) Type of Afib matters! Afib is a progressive disease Referring Physician: GP, Cardiologist Two Distinct Patient Profiles © 2020 AtriCure, Inc. All rights reserved. STRUCTURAL HEART ISSUE Surgery required – Afib corrected at same time (Valve, CABG) NO STRUCT
Slide 6: Significant Global Market Opportunity
Significant Global Market Opportunity © 2020 AtriCure, Inc. All rights reserved. Total US market opportunity $3B+ annually International market $2B+ annually International Market Focus Penetration of large markets first Expand product availability Improve market access via reimbursement Continued bu
Slide 7: US Market Opportunity by Segment
~$350M Pain Management Procedures (Ablation) $2B+ and growing Standalone Hybrid Procedures (Ablation/LAAM) $700-800M Concomitant Open Procedures (Ablation/LAAM) US Market Opportunity © 2020 AtriCure, Inc. All rights reserved. Medicine is effective Steady Growth in penetration of Cardiac Surgery Mark
Slide 8: History of Strong Financial Performance
History of Strong Financial Performance 5-year CAGR > 15% growth 71.6% Gross Margin 71.6% 73.0% 72.2% 73.8% © 2020 AtriCure, Inc. All rights reserved. Revenue Growth Consistent Revenue Growth Strong history of double-digit YoY growth Steady Improvement to Gross Margin $250M Cash & Investments at Sep
Slide 9: Innovative and Expanding Product Portfolio
Innovative and Expanding Product Portfolio © 2020 AtriCure, Inc. All rights reserved. Ablation 2000 to 2015: Foundation in surgical Afib tools Future pipeline expansion across franchises Appendage Management 2015 and Beyond: Building the future in minimally invasive therapies Innovation toward less
Slide 10: CONVERGE Overview
CONVERGE Overview PRIMARY ENDPOINTS Effectiveness Primary efficacy endpoint is success or failure to be AF/AT/AFL free absent class I and III AADs except for a previously failed or intolerant class I or III AAD with no increase in dosage following the 3 month blanking period through the 12 months po
Slide 11: CONVERGE Trial Conclusions
Only multicenter, randomized controlled clinical trial (RCT) comparing the effectiveness of combined epicardial and endocardial ablation to endocardial catheter ablation alone for advanced Afib Demonstrates that the Hybrid Convergent procedure has a compelling safety profile and superior effectivene
Slide 12: aMAZE Overview
aMAZE Overview © 2020 AtriCure, Inc. All rights reserved. SUPERIORITY TRIAL designed to evaluate safety and effectiveness of the LARIAT System to percutaneously isolate and ligate the Left Atrial Appendage for the treatment of persistent or longstanding persistent Afib Acquired SentreHEART® August 2
Slide 13: Growth Drivers: Cryo Nerve Block for Pain Management
Growth Drivers Q1 2019 launch of cryoSPHERE probe Dedicated commercial team ~$350M U.S. market opportunity* Continuing to gather data to support evidence development of the therapy Potential to contribute to combatting the opioid epidemic – 1 in 7 thoracic surgery patients become reliant upon opioid
Slide 14: Expecting An Exciting Future
Expecting An Exciting Future… Core double-digit growth business with accelerators in EP landscape (Hybrid Convergent + aMAZE) © 2020 AtriCure, Inc. All rights reserved. AtriCure Pillars Foundation of our past and strengthening our future Innovation Expanding pipeline to drive Open ablation penetrati
Slide 15: Thank You!
Thank You! © 2020 AtriCure, Inc. All rights reserved.
Slide 16: Supplemental Information
Supplemental Information Note that citations/references for any comments, statistics, or figures in this presentation are available upon request. © 2020 AtriCure, Inc. All rights reserved.
Slide 17: COVID-19 Response
COVID-19 Response © 2020 AtriCure, Inc. All rights reserved. Operationally, financially, and strategically positioning AtriCure for long-term growth Delayed certain capital investments Temporarily reduced executive and board compensation Limited other non-essential operating expenses where possible
Slide 18: US Concomitant Market Opportunity
US annual cardiac surgery volume steady over the past 5 years with shifts in procedure types10 Pre-Op Afib occurs frequently in cardiac surgery patients11 New onset Post-Op Afib is a well-documented complication of cardiac surgery, even if patients do not present with pre-op Afib12 US Concomitant Ma
Slide 19: US Standalone Market Opportunity
US Standalone Market Opportunity © 2020 AtriCure, Inc. All rights reserved. Market opportunity in analysis at left considers: Addition of ablation and LAAM to existing catheter ablation procedures Catheter ablation procedures have grown 10-15% annually16 Incremental penetration of advanced Afib pati
Slide 20: The CONVERGENT Approach
The CONVERGENT Approach © 2020 AtriCure, Inc. All rights reserved.
Slide 21: The LARIAT Procedure
4 The LARIAT Procedure © 2020 AtriCure, Inc. All rights reserved. Procedure pics? Access: Routine percutaneous techniques for pericardial and transseptal access are performed using fluoroscopy and transesophageal echocardiography. Delivery: Two magnet-tipped guidewires (FindrWIRZ®) are attached to s
Slide 22: The Cox-Maze IV Procedure
The Cox-Maze IV Procedure © 2020 AtriCure, Inc. All rights reserved.
Slide 23: Endnotes
Endnotes: © 2020 AtriCure, Inc. All rights reserved. Note Reference 1 Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study 2 The American Journal of Cardiology (2013), 112: 1142-1147 3 Kim MH et al., “Estimation of Total Incremental Health Care Costs in Patients with